Abstract: Nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof in which a therapeutically effective amount of the nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof is administered to the subject.

Abstract: Nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of SAPHO syndrome in a subject in need thereof. The subject suffers from one first symptom which is an osteoarticular symptom of SAPHO syndrome selected from synovitis, osteitis, primitive inflammatory osteitis, hyperostosis, axial spondyloarthritis, arthritis, enthesitis, and diffuse idiopathic skeletal hyperostosis (DISH)-like non-marginal enthesophytes, and at least one second symptom of SAPHO syndrome different from the first system.

Abstract: The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and/or prevention of a red blood cell disorder, especially sickle cell disease.

Abstract: The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and/or prevention of a red blood cell disorder, especially sickle cell disease.

Abstract: The present disclosure relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present disclosure further relates to pharmaceutical compositions including compounds of Formula (I) for use in the treatment and/or prevention of a red blood cell disorder, especially sickle cell disease.